The impact of COVID-19 on the new diagnoses of melanoma
Christophe Gedeah, Thomas Damsin, Gilles Absil, Joan Somja, Patrick Collins, Andrée Rorive, Nathalie Marchal, Laurence Seidel, Arjen Nikkels
Abstract
findings may, as in the present case, indicate a combination of traits indicative of psoriasis and toxicoderma In most of these patients, the lesions can be controlled with topical therapy In the present case, however, the skin condition not only worsened when the anticancer therapy was stopped (perhaps because cessation coincided with the withdrawal of oral corticosteroids) but also prevented the use of alternative therapies to halt tumour progression. Ixekizumab is an anti-IL-17A drug approved for the treatment of moderate-to-severe plaque psoriasis. It is highly effective and produces a rapid clinical response, achieving a 75-90% reduction in PASI score in 70-90% of patients at 12 weeks [9]. A case of prembrolizumab-induced psoriasis treated with secukinumab is documented in the literature [10]. However, there are no previous reports of ixekizumab use for psoriasis triggered by tremelimumab and durvalumab. In the present case, given the urgent need to obtain clinical remission, ixekizumab was administered, achieving complete resolution of the skin condition within a few weeks. Biologic therapy may be a rapid and effective therapeutic option in patients with severe psoriasis triggered by immunotherapy, although more information is needed on long-term outcome and safety in these patients.